Examples of 'bivalirudin' in a sentence
Meaning of "bivalirudin"
bivalirudin (noun) - In English, 'bivalirudin' is a medication classified as a direct thrombin inhibitor. It is used as an anticoagulant in patients undergoing certain medical procedures or conditions, such as percutaneous coronary intervention. Bivalirudin helps prevent blood clots from forming and is administered intravenously under medical supervision. For example, 'The patient received bivalirudin before the cardiac procedure.'
Show more definitions
- A specific and reversible direct thrombin inhibitor, a synthetic congener of hirudin.
How to use "bivalirudin" in a sentence
Basic
Advanced
bivalirudin
Bivalirudin inhibits each of these thrombin effects.
It is unknown whether bivalirudin is excreted in human milk.
There are no gender effects in the pharmacokinetics of bivalirudin.
Do not use bivalirudin without first diluting it.
Temperature had no detectable effect on bivalirudin clearance.
Bivalirudin is a synthetic peptide with the following attributes.
It is not known whether bivalirudin is excreted in human milk.
Bivalirudin is a synthetic polypeptide analogous to hirudin.
Unfractionated heparin or bivalirudin was used for procedural anticoagulation.
It contains the active substance bivalirudin.
Intravenous administration of bivalirudin produces measurable anticoagulation within minutes.
Medicinal products with dose concentration incompatibilities to bivalirudin.
Bivalirudin is rapidly distributed between plasma and extracellular fluid.
No mortality or adverse effects attributable to bivalirudin were observed in two.
The bioavailability of bivalirudin for intravenous use is complete and immediate.
See also
Angiox is a medicine that contains the active substance bivalirudin.
Angiox contains a substance called bivalirudin which is an antithrombotic medicine.
Bivalirudin for injection.
The active substance is bivalirudin.
Pharmacokinetic parameters for bivalirudin in patients with normal and impaired renal function.
No formal drug interaction studies have been carried out with bivalirudin.
Pharmacokinetic parameters for bivalirudin in patients with normal and impaired.
Bivalirudin remains active and is not neutralised by products of the platelet release reaction.
There are no adequate data from the use of bivalirudin in pregnant women.
Patients receiving bivalirudin had fewer adverse events compared to patients that received heparin.
There are no or limited data from the use of bivalirudin in pregnant women.
Bivalirudin upon cell transplantation improves cell transplantation efficiency and cell engraftment potential.
No patient used bivalirudin.
In clinical studies bivalirudin has been shown to provide adequate anticoagulation during PCI procedures.
The ACT value is positively correlated with the dose and plasma concentration of bivalirudin administered.
For medical information on Bivalirudin please open this link.
Bivalirudin was tested in patients with NSTEACS in the ACUITY study.
The systemic clearance of bivalirudin decreases with glomerular filtration rate GFR.
Bivalirudin exhibits linear pharmacokinetics following IV administration to patients undergoing PTCA.
What Angiox contains The active substance is bivalirudin.
The pharmacodynamic effects of bivalirudin may be assessed using measures of anticoagulation including the ACT.
Post-marketing adverse reactions reported for bivalirudin.
As expected with bivalirudin use we observed a substantial increase in TT and limited in PT.
In the event of major bleeding, treatment with bivalirudin should be immediately discontinued.
Bivalirudin is metabolized by proteases, including thrombin.
Coagulation times return to baseline approximately 1 hour following cessation of bivalirudin administration.
Bivalirudin dose is body weight adjusted in mg / kg.
No long-term studies in animals have been performed to evaluate the carcinogenic potential of bivalirudin.
Bivalirudin has a linear anticoagulating dose-response behavior.
The following six medicinal products show dose-concentration incompatibilities with bivalirudin.
Bivalirudin is a short, synthetic peptide.
The thrombin inhibitor is selected from the group consisting of bivalirudin and hirudin, preferably bivalirudin.
However, bivalirudin was not mutagenic or clastogenic in standard assays for such effects.
Serious bleeding, including bleeding with a fatal outcome has been reported in post-marketing experience for bivalirudin.
Bivalirudin is supplied in single-use vials as a white lyophilized cake, which is sterile.
